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I am old enough to have taken partin the international project to sequencethe first eukaryotic genome—that of
Saccharomyces cerevisiae—which was rele-
ased in 1996. Twenty years later, scientists
from academic and commercial institutions
are now involved in the first wholesale
construction of a eukaryotic genome: the
Yeast 2.0 Project [1]. The construction of
whole genomes from scratch is defined as a
bottom-up approach in synthetic biology.
One of the aims of such work is to reduce
genome size and construct a minimal cell
factory for industrial applications. These
synthetic yeast chromosomes will have
unique features to allow scientists to easily
reshuffle, eliminate or add new genes [2] in
order to engineer cells for efficient produc-
tion of a desired compound. Synthetic bio-
logists also use a top-down approach to
insert functional biological components into
natural genomes. This has been used in
yeast to produce natural molecules of phar-
maceutical value, such as artemisinin acid
[3]. Currently, many compounds are not
chemically synthesized because it is cheaper
and more efficient to extract them from
plants. The products of synthetic biology
could easily replace plants as the source,
especially as yeast fermentation is a matter
of days, while plants need months or years
to grow.
Saccharomyces cerevisiae is a generally
safe organism that has been used for thou-
sands of years to produce wine, beer, bread
and chocolate. But the recent publication of an
elegant piece of synthetic biology could trans-
form this mostly harmless organism into an
“illicit” one: Smoke and co-workers have
expressed in yeast the entire biosynthetic path-
way of thebaine, a precursor of morphine, and
the semi-synthetic opioid hydrocodone, by
combining genes from plants, mammals and
bacteria [4]. They used yeast as a production
platform because it allowed them to perform
spatial engineering—that is, expressing
heterologous genes in different organelles
such as mitochondria and the endoplasmic
reticulum. This amazing achievement opens
up the possibility to produce codeine or
morphine by fermentation [5, 6]. These drugs,
which are of great pharmaceutical value, are
used for pain relief and are usually extracted
from the plant Papaver somniferum because
their chemical synthesis is not commercially
competitive. At present, the yields from yeast
are not high, but it seems inevitable that
bottom-up and top-down technology will even-
tually combine to introduce the entire bio-
synthetic opiates pathway into a yeast
synthetic genome to generate cells that over-
produce morphine—which is classified by
most countries as a dangerous narcotic, aside
from its medical use, and can be processed
into heroine.
Is the scientific community ready to
manage the consequences of the fruits of
synthetic biology? I see two concerns on
which we should reflect. First, morphine-
producing yeast are a clear case of dual-use
technology: they could either be used to
produce cheaper, less addictive, safer and
more effective analgesics, or they could be
used to produce illicit drugs from ubiquitous
substrates by fermentation. There are
historic examples from periods of prohibi-
tion in the USA and elsewhere that show
that it is nigh impossible to stop bootleggers
from abusing cheap and easy-to-use techno-
logy to produce illegal narcotics. Unfortu-
nately, technology does not come much
cheaper or easier than yeast cells, which can
be easily cultured and transported—sealed
in a sterile pot of anti-wrinkle cream on an
airplane, for example, as I have done with
my favourite yeast mutants. The authors of
the current study were well aware of the
dual-use nature of their work, so they
contacted technology policy experts [7] and
have taken a number of precautions to avoid
illicit use of such strains.
Second, I believe that there should be a
broad and ongoing dialogue between
researchers, health experts, scientists and
law enforcement agencies in order to moni-
tor the progress of synthetic biology projects
with dual-use applications; for instance, a
yeast cell factory able to produce botulinum
toxin for therapeutic use could also be used
as a biological weapon. International
regimes on dual-use control, such as the
Australia Group, are already monitoring
new and evolving technologies, including
synthetic biology, given their potential for
abuse. I hope that, in the future, engineered
yeast strains to produce dual-use molecules
or illicit drugs, which are so far not included
in any controlled biological agent lists,
would be at least restricted to facilities or
laboratories with an appropriate licence.
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